IN2014DN10576A - - Google Patents

Info

Publication number: IN2014DN10576A
Authority: IN; India
Prior art keywords: bruton; inhibitors; compositions; useful; same
Prior art date: 2012-06-08

Application number

Other languages

English (en)

Inventor

Brian T Hopkins

Patrick Conlon

Timothy R Chan

Tracy J Jenkins

Xiongwei Cai

Michael Humora

Xianglin Shi

Ross A Miller

Andrew Thompson

Original Assignee

Biogen Idec Inc

Sunesis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-08

Filing date

2013-06-07

Publication date

2015-08-28

2013-06-07 Application filed by Biogen Idec Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Idec Inc

2015-08-28 Publication of IN2014DN10576A publication Critical patent/IN2014DN10576A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

IN10576DEN2014 2012-06-08 2013-06-07 IN2014DN10576A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261657360P	2012-06-08	2012-06-08
PCT/US2013/044800 WO2013185084A1 (en)	2012-06-08	2013-06-07	Pyrimidinyl tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
IN2014DN10576A true IN2014DN10576A (es)	2015-08-28

Family

ID=49712704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN10576DEN2014 IN2014DN10576A (es)	2012-06-08	2013-06-07

Country Status (30)

Country	Link
US (5)	US9394277B2 (es)
EP (3)	EP3753934A1 (es)
JP (6)	JP6214643B2 (es)
KR (4)	KR20200043497A (es)
CN (3)	CN104540385B (es)
AR (1)	AR091273A1 (es)
AU (5)	AU2013271407B2 (es)
BR (2)	BR112014030655B1 (es)
CA (2)	CA2875799C (es)
CY (1)	CY1120638T1 (es)
DK (1)	DK2858499T3 (es)
EA (2)	EA027823B1 (es)
ES (2)	ES2684268T3 (es)
HK (1)	HK1209284A1 (es)
HR (1)	HRP20181294T1 (es)
HU (1)	HUE039897T2 (es)
IL (2)	IL235938B (es)
IN (1)	IN2014DN10576A (es)
LT (1)	LT2858499T (es)
MX (2)	MX363672B (es)
NZ (1)	NZ702715A (es)
PH (2)	PH12014502699B1 (es)
PL (1)	PL2858499T3 (es)
PT (1)	PT2858499T (es)
RS (1)	RS57978B1 (es)
SG (2)	SG10201708535UA (es)
SI (1)	SI2858499T1 (es)
TW (3)	TWI792158B (es)
WO (1)	WO2013185084A1 (es)
ZA (1)	ZA201409255B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5699149B2 (ja) *	2009-09-04	2015-04-08	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
EP2632898A4 (en)	2010-10-29	2014-04-02	Biogen Idec Inc	HETEROCYCLIC TYROSINE KINASE HEMMER
AR091273A1 (es)	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
WO2013185082A2 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Inhibitors of bruton's tyrosine kinase
AU2014362231B2 (en) *	2013-12-11	2019-04-04	Biogen Ma Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015151006A1 (en)	2014-03-29	2015-10-08	Lupin Limited	Substituted purine compounds as btk inhibitors
WO2015170266A1 (en)	2014-05-07	2015-11-12	Lupin Limited	Substituted pyrimidine compounds as btk inhibitors
MA40301B1 (fr) *	2014-10-24	2019-12-31	Bristol Myers Squibb Co	Composés indolecarboxamides utiles comme inhibiteurs de kinase
RU2019104758A (ru)	2016-07-21	2020-08-21	Байоджен Ма Инк.	Сукцинатные формы и композиции ингибиторов тирозинкиназы брутона
JP7331843B2 (ja)	2018-04-27	2023-08-23	小野薬品工業株式会社	Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
CA3224949A1 (en)	2018-07-31	2020-02-06	Loxo Oncology, Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CA3129665A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en)	2019-11-08	2022-09-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
WO2022140246A1 (en)	2020-12-21	2022-06-30	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
WO2022212893A1 (en)	2021-04-02	2022-10-06	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
WO2023081709A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Vecabrutinib for the treatment of graft-versus-host disease
WO2023081715A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023110970A1 (en)	2021-12-14	2023-06-22	Netherlands Translational Research Center Holding B.V	Macrocyclic btk inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1624A (en) *		1840-06-10		Cooking-stove
US4528138A (en)	1984-06-20	1985-07-09	E. R. Squibb & Sons, Inc.	16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en)	1986-07-30	1990-03-27	Alcon Laboratories, Inc.	Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr)	1985-10-03	1988-12-02	Merck Sharp & Dohme	Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de)	1991-01-15	1996-09-15	Alcon Lab Inc	Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en)	1991-03-27	1993-05-18	Alcon Laboratories, Inc.	Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en)	2000-11-21	2005-07-19	Sunesis Pharmaceuticals, Inc.	Extended tethering approach for rapid identification of ligands
CN1481377A (zh)	2000-03-17	2004-03-10	��˹�ж�-��˹˹��ҩƷ��˾	作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
MY145722A (en)	2000-04-27	2012-03-30	Abbott Lab	Diazabicyclic central nervous system active agents
OA12292A (en)	2000-06-26	2003-11-11	Pfizer Prod Inc	PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
PE20020507A1 (es) *	2000-10-17	2002-06-25	Schering Corp	Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002363236A1 (en) *	2001-10-30	2003-05-12	Millennium Pharmaceuticals, Inc.	Compounds, pharmaceutical compositions and methods of use therefor
MXPA04004019A (es)	2001-10-31	2004-07-08	Bayer Healthcare Ag	Derivados de pirimido?4,5-b?indol.
SG182004A1 (en)	2003-01-14	2012-07-30	Arena Pharm Inc	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DE602004022318D1 (de)	2003-10-14	2009-09-10	Supergen Inc	Proteinkinaseinhibitoren
US20080253960A1 (en) *	2004-04-01	2008-10-16	The Trustees Of The University Of Pennsylvania Center For Technology Transfer	Lipoprotein-Based Nanoplatforms
CA2563699C (en)	2004-04-23	2014-03-25	Exelixis, Inc.	Kinase modulators and method of use
FR2870541B1 (fr)	2004-05-18	2006-07-14	Proskelia Sas	Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es)	2004-09-09	2006-11-29	Sanofi Aventis	Derivados de 2- morfolino-4-pirimidona
AU2005304784B2 (en) *	2004-11-04	2011-03-24	Vertex Pharmaceuticals Incorporated	Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
CN102558075A (zh)	2004-12-03	2012-07-11	先灵公司	作为cb1拮抗剂的取代哌嗪
ATE543821T1 (de)	2004-12-28	2012-02-15	Exelixis Inc	Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
WO2006071875A1 (en)	2004-12-29	2006-07-06	Millennium Pharmaceuticals, Inc.	Compounds useful as chemokine receptor antagonists
US7423043B2 (en) *	2005-02-18	2008-09-09	Lexicon Pharmaceuticals, Inc.	4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en)	2005-06-10	2006-12-14	Gaul Michael D	Aminopyrimidines as kinase modulators
US20060281700A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
MY167260A (en)	2005-11-01	2018-08-14	Targegen Inc	Bi-aryl meta-pyrimidine inhibitors of kinases
KR20080081321A (ko) *	2005-12-21	2008-09-09	쉐링 코포레이션	Ｈ3 길항제/역 작용제 및 식욕 억제제의 조합물
US20080076924A1 (en)	2006-06-30	2008-03-27	Patrick Betschmann	Piperazines as P2X7 antagonists
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
WO2008014307A2 (en)	2006-07-26	2008-01-31	Novartis Ag	Inhibitors of undecaprenyl pyrophosphate synthase
US20100160292A1 (en)	2006-09-11	2010-06-24	Cgi Pharmaceuticals, Inc	Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
ES2585902T3 (es)	2006-09-22	2016-10-10	Pharmacyclics Llc	Inhibidores de tirosina cinasa de Bruton
CA2679807A1 (en) *	2007-03-02	2008-09-12	Schering Corporation	Piperidine derivatives and methods of use thereof
WO2008116064A2 (en)	2007-03-21	2008-09-25	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
WO2008150799A1 (en)	2007-06-01	2008-12-11	Smithkline Beecham Corporation	Imidazopyridine kinase inhibitors
MX2010008197A (es) *	2008-02-05	2010-08-23	Hoffmann La Roche	Nuevas piridinonas y piridazinonas.
EP2283358B1 (en)	2008-04-29	2015-04-22	Immunexcite, Inc.	Immunomodulating compositions and methods of use thereof
CN102159214A (zh) *	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2010068788A1 (en) *	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Heterocyclic amides as btk inhibitors
EA019041B1 (ru)	2008-12-19	2013-12-30	Бристол-Маерс Сквибб Компани	Карбазолкарбоксамидные соединения, применимые в качестве ингибиторов киназы
JP5908728B2 (ja)	2009-01-06	2016-04-26	ダナファーバーキャンサーインスティテュートインコーポレイテッド	ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
JP2012528103A (ja)	2009-05-25	2012-11-12	サンド・アクチエンゲゼルシヤフト	セフトビプロールメドカリルの製造方法
US9029359B2 (en)	2009-09-04	2015-05-12	Biogen Idec Ma, Inc.	Heteroaryl Btk inhibitors
JP5699149B2 (ja)	2009-09-04	2015-04-08	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
US8685880B2 (en)	2010-06-30	2014-04-01	Chevron U.S.A. Inc.	On-site drying of aqueous salt for ionic liquid make-up
EP2632898A4 (en)	2010-10-29	2014-04-02	Biogen Idec Inc	HETEROCYCLIC TYROSINE KINASE HEMMER
WO2013185082A2 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Inhibitors of bruton's tyrosine kinase
AR091273A1 (es) *	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
AU2014362231B2 (en)	2013-12-11	2019-04-04	Biogen Ma Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3444251B1 (en)	2013-12-11	2023-06-07	Biogen MA Inc.	Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20170298446A1 (en)	2014-10-03	2017-10-19	Ohio State Innovation Foundation	Biomarkers of bruton tyrosine kinase inhibitor resistance

2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en active Application Filing
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en unknown
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en active Pending
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh active Active
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh active
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko active Application Filing
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en active Active
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh active
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active IP Right Grant
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh active
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko active IP Right Grant
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt active IP Right Grant
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Application Discontinuation
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja active Active
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en active Active
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699B1/en unknown
- 2014-12-08 MX MX2019003618A patent/MX2019003618A/es unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
2015
- 2015-10-20 HK HK15110301.6A patent/HK1209284A1/xx unknown
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en active Active
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-07-09 PH PH12018501463A patent/PH12018501463A1/en unknown
- 2018-08-08 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en active Active
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
2021
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en active Pending
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en active Pending
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending

Also Published As

Publication number	Publication date
JP6214643B2 (ja)	2017-10-18
HK1209284A1 (en)	2016-04-01
EP2858499B1 (en)	2018-05-16
CN113549055A (zh)	2021-10-26
JP2019077728A (ja)	2019-05-23
US9394277B2 (en)	2016-07-19
PH12018501463A1 (en)	2019-03-04
EA027823B1 (ru)	2017-09-29
JP2023052415A (ja)	2023-04-11
AU2017201536A1 (en)	2017-03-23
KR20210072139A (ko)	2021-06-16
TW201410668A (zh)	2014-03-16
BR122021002178B1 (pt)	2022-03-22
AU2013271407B2 (en)	2016-12-08
BR112014030655B1 (pt)	2021-04-20
US20160304494A1 (en)	2016-10-20
NZ702715A (en)	2016-11-25
EP3753934A1 (en)	2020-12-23
HUE039897T2 (hu)	2019-02-28
ES2684268T3 (es)	2018-10-02
TWI719209B (zh)	2021-02-21
US9944622B2 (en)	2018-04-17
SI2858499T1 (sl)	2018-10-30
JP2021073298A (ja)	2021-05-13
TWI592406B (zh)	2017-07-21
EP2858499A4 (en)	2016-01-20
RS57978B1 (sr)	2019-01-31
AU2022275504A1 (en)	2023-01-05
MX2019003618A (es)	2019-07-18
AU2019203476B2 (en)	2021-01-28
AU2021202412A1 (en)	2021-05-20
HRP20181294T1 (hr)	2018-10-05
KR20150036020A (ko)	2015-04-07
MX363672B (es)	2019-03-29
TW201805279A (zh)	2018-02-16
US20230174511A1 (en)	2023-06-08
CN104540385B (zh)	2018-06-05
BR112014030655A8 (pt)	2018-01-02
EP2858499A1 (en)	2015-04-15
CN109305959A (zh)	2019-02-05
LT2858499T (lt)	2018-09-10
EA201492056A1 (ru)	2015-05-29
PH12014502699A1 (en)	2015-02-02
PT2858499T (pt)	2018-10-24
CA3108186A1 (en)	2013-12-12
AU2017201536B2 (en)	2019-03-07
SG10201708535UA (en)	2017-11-29
EA201790418A1 (ru)	2017-11-30
BR112014030655A2 (pt)	2017-06-27
KR102102587B1 (ko)	2020-04-22
US20150158843A1 (en)	2015-06-11
KR20220154850A (ko)	2022-11-22
PL2858499T3 (pl)	2019-03-29
JP2021073299A (ja)	2021-05-13
CN109305959B (zh)	2022-02-08
CN104540385A (zh)	2015-04-22
DK2858499T3 (en)	2018-08-20
CA2875799C (en)	2021-03-23
US10618887B2 (en)	2020-04-14
EP3385263A1 (en)	2018-10-10
KR20200043497A (ko)	2020-04-27
AR091273A1 (es)	2015-01-21
US20210017155A1 (en)	2021-01-21
AU2019203476A1 (en)	2019-06-06
EP3385263B1 (en)	2020-07-22
ES2834333T3 (es)	2021-06-17
TWI792158B (zh)	2023-02-11
WO2013185084A1 (en)	2013-12-12
IL235938B (en)	2020-10-29
ZA201409255B (en)	2015-12-23
JP2015518903A (ja)	2015-07-06
IL277951A (en)	2020-11-30
MX2014015044A (es)	2015-09-22
US20190047986A1 (en)	2019-02-14
IL235938A0 (en)	2015-02-01
KR102468430B1 (ko)	2022-11-21
CA2875799A1 (en)	2013-12-12
SG11201408173WA (en)	2015-01-29
AU2013271407A1 (en)	2015-01-22
PH12014502699B1 (en)	2015-02-02
TW202142535A (zh)	2021-11-16
JP2017193583A (ja)	2017-10-26
CY1120638T1 (el)	2019-12-11

Publication	Publication Date	Title
PH12018501463A1 (en)	2019-03-04	Pyrimidinyl tyrosine kinase inhibitors
MY179781A (en)	2020-11-13	Biaryl inhibitors of bruton's tyrosine kinase
PH12015502041B1 (en)	2016-01-18	Heteroaryl compounds and uses thereof
MX2014010849A (es)	2014-12-10	Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
PH12014502697B1 (en)	2015-01-26	New diazaspirocycloalkane and azaspirocycloalkane
IN2015DN00127A (es)	2015-05-29
MX2015015421A (es)	2016-06-21	Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MX2016003843A (es)	2017-02-15	Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MY160734A (en)	2017-03-15	Besylate salt of a btk inhibitor
MX2015015417A (es)	2016-06-21	Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
WO2013185082A3 (en)	2014-04-03	Inhibitors of bruton's tyrosine kinase
SG179085A1 (en)	2012-04-27	Pi3 kinase inhibitors and uses thereof
IL259863B (en)	2020-06-30	Polycyclic compounds as inhibitors of proton tyrosine kinase
WO2012122383A3 (en)	2012-12-27	Pi3 kinase inhibitors and uses thereof
EA201590268A1 (ru)	2015-05-29	Ариллактамные ингибиторы киназы
MA39824A (fr)	2017-02-08	Composés azole amido-substitués
MX2019000884A (es)	2019-09-04	Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
NZ743260A (en)	2019-06-28	Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors
NZ737572A (en)	2019-08-30	Intermediate compounds for the preparation of bipiperidine-2-one compounds